David H. Fitchett, MD and Cardiologist at St. Michael's Hospital at the University of Toronto discusses the effect of empagliflozin on mortality and causes of death in patients with type 2 diabetes at high cardiovascular risk at the American College of Cardiology 65th Annual Scientific Session & Expo (ACC.16).

MDLinx Conference Coverage - American College of Cardiology 65th Annual Scientific Session & Expo (ACC.16): http://www.mdlinx.com/cardiology/conf...

MDLinx: http://www.mdlinx.com/
Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/
M3 USA: http://usa.m3.com/

Follow MDLinx:
Facebook -   / mdlinx  
Twitter -   / mdlinx  
Google+ - https://plus.google.com/+Mdlinx/